Does Wegovy have GIP receptors in its mechanism?

Why GIP matters, and what it does in the body

GIP and GLP-1 are both incretin hormones released by the gut after eating. GLP-1 slows gastric emptying, reduces appetite and helps regulate blood sugar. GIP does some of the same, but it also acts on fat tissue and may amplify the brain's satiety signals through a slightly different route. For years, GIP was considered a minor player compared to GLP-1. That view changed when researchers found that activating both receptors at once produced metabolic effects neither pathway achieved alone.

Wegovy's mechanism, well-documented in the NHS patient information for semaglutide, is GLP-1 only. Semaglutide is a modified version of the human GLP-1 hormone; it binds to GLP-1 receptors in the pancreas, gut, and brain. There is no GIP component. It works, and the STEP 1 trial published in the New England Journal of Medicine recorded an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, a meaningful result for a single-receptor medicine.

The question of GIP became sharper once tirzepatide's data appeared. Understanding what Wegovy contains at a molecular level is the right starting point if you want to make sense of those comparisons, the ingredient detail is covered in the full breakdown of what Wegovy contains.

What head-to-head data shows when GIP is added to GLP-1

The clearest evidence comes from SURMOUNT-5, a 72-week open-label trial published in the New England Journal of Medicine in 2025. It randomised 751 adults with obesity and no diabetes to either tirzepatide or semaglutide 2.4mg. Tirzepatide produced a greater average percentage weight loss. That gap is the real-world consequence of adding GIP receptor agonism to GLP-1 receptor agonism, at least at the doses and timeframes studied.

Novo Nordisk has since gained MHRA approval for a 7.2mg semaglutide dose, with trials reporting around 20.7% average weight loss over 72 weeks. That narrows the gap considerably. The GIP question therefore does not have a tidy, permanent answer; it is an evolving picture as both medicines move through higher-dose regimens. What the data does settle is the mechanistic one: Wegovy, at any dose, does not have GIP activity. The comparison to explore in more depth is on the semaglutide overview.

For the GLP-1 side of the mechanism specifically, the explanation of Wegovy's GLP-1 action covers exactly how that single pathway drives appetite reduction.

Does the absence of GIP affect who Wegovy suits?

Not necessarily. Wegovy has a strong evidence base, a well-understood side-effect profile, and a licensed dose range from 0.25mg up to the newly approved 7.2mg. NICE recommended semaglutide (TA875) for eligible adults within specialist weight management services. Many people do very well on a GLP-1-only medicine, and the absence of a second receptor pathway is not a clinical disadvantage in every case.

A prescriber's job is to weigh the evidence against your individual health picture: other medicines you take, your BMI, any weight-related conditions, and how you responded to treatment previously. The GIP-versus-GLP-1 distinction is one factor, not the only one. If you are weighing up the options, our Wegovy treatment page and the broader weight-loss treatment overview set out both licensed medicines side by side.

Cost is sometimes a deciding factor too. The Wegovy cost page covers what private treatment typically involves, including what a legitimate price should include beyond just the pen. One thing our prescribers hear regularly: people are surprised that two medicines targeting different receptor combinations can sit at similar private price points. Worth knowing before you decide.

What to ask in your consultation

If the GIP question brought you here, you are already asking the right kind of thing. Good clinical conversations about weight-loss treatment involve mechanism, not just milligrams. A prescriber can explain whether the dual-agonist approach makes sense for your situation, or whether a GLP-1-only pathway is the stronger fit.

These are prescription-only medicines. The consultation is where the actual decision gets made, not before it. Our clinical team, described on the clinical team page, reviews every consultation personally. There are no algorithmic approvals. If you want to understand the hormonal classification of these medicines further before speaking to a prescriber, the Wegovy and hormones page is a useful read.

Speak to our prescribers if you'd like a same-day clinical assessment of which medicine (if either) is appropriate for you. The consultation is free, and there is no obligation to proceed. Start your free consultation here.